Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 54

Inclusion Criteria

Inclusion Criteria: - Patients aged 6 months to =< 65 years at time of consent. - Acute myelogenous leukemia (AML): - Complete first remission (CR1), complete second remission (CR2) or greater (CR2+), must have < 5% marrow blasts at the time of transplant. - Patients in morphologic remission with persistent cytogenetic, flow cytometric, or molecular aberrations are eligible. - Acute lymphoblastic leukemia (ALL): - Complete first remission (CR1) at high risk for relapse such as any of the following: - Presence of any high-risk cytogenetic abnormalities such as t(9;22), t(1;19), t(4;11) or other MLL rearrangements (11q23) or other high-risk molecular abnormality. - Failure to achieve MRD- complete remission after induction therapy. - Persistence or recurrence of minimal residual disease on therapy. - Any patient unable to tolerate consolidation and/or maintenance chemotherapy as would have been deemed appropriate by the treating physician. - Other high-risk features not defined above. - Complete second remission (CR2) or greater (CR2+). - Note: ALL with less than 5% blasts at time of transplant but persistent cytogenetic, flow cytometric or molecular aberrations are eligible. - Other acute leukemias: Acute leukemias of ambiguous lineage or mixed phenotype with less than 5% blasts. Leukemias in morphologic remission with persistent cytogenetic, flow cytometric or molecular aberrations are eligible. - Chronic Myeloid Leukemia (CML): Excluding refractory blast crisis. To be eligible in first chronic phase (CP1) patient must have failed or be intolerant to tyrosine kinase inhibitor therapy. - Myelodysplastic syndromes (MDS) and myeloproliferative disorders (MPD) other than myelofibrosis: - MDS/MPD overlap syndromes without myelofibrosis. - MDS/ MPD patients must have less than 10% bone marrow myeloblasts and absolute neutrophil count (ANC) > 0.2 (growth factor supported if necessary) at transplant work-up. - Non-Hodgkin lymphoma (NHL) at high-risk of relapse or progression if not in remission: - Eligible patients with aggressive histology (such as, but not limited to, diffuse large B-cell NHL, mantle cell NHL, and T-cell histology) in CR by PET/CT imaging. - Eligible patients with indolent B-cell NHL (such as, but not limited to, follicular, small cell or marginal zone NHL) will have 2nd or subsequent progression with PR or CR by PET/CT imaging. - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) in morphologic remission. - Only for adult patients, to prevent graft rejection, patients who received only non-lymphodepleting agents for their malignancy (hypomethylating agents, venetoclax, hydroxyurea, TKIs etc.), or patients who received lymphodepleting chemotherapy > 3 months prior to scheduled admission, may receive fludarabine 25 mg/m^2 daily x 3 days for lymphodepletion 14-42 days (aiming for 2-4 weeks) at the discretion of the principal investigator (PI). - For patients > 18 years old, Karnofsky score = 70%. For patients =< 18 years old, Lansky score = 50%. - Calculated creatinine clearance > 70 ml/min. - Bilirubin < 1.5 mg/dL (unless benign congenital hyperbilirubinemia or hemolysis). - Alanine transaminase (ALT) < 3 x upper limit of normal (ULN). - For patients > 18 years old, pulmonary function (spirometry and corrected diffusing capacity for carbon monoxide [DLCO]) > 60% predicted. For patients =< 18 years old, or any patient unable to perform pulmonary function tests, O2 saturation > 92% on room air. - Left ventricular ejection fraction > 50%. - Albumin > 3.0 g/dL. - For patients > 18 years old, Hematopoietic Cell Transplantation Comorbidity index (HCT-CI) =< 5. - UCB units will be selected according to current umbilical cord blood graft selection algorithm. One or two UCB units may be used to achieve the required cell dose. - The UCB graft is matched at 4-6 HLA-A, B, DRB1 antigens with the recipient. This may include 0-2 antigen mismatches at the A or B or DRB1 loci. Unit selection based on cryopreserved nucleated cell dose and HLA-A, B, DRB1 using intermediate resolution A, B antigen and DRB1 allele typing. Exclusion Criteria: - Diagnosis of myelofibrosis or other malignancy with moderate-severe bone marrow fibrosis. - Patients persistent with central nervous system (CNS) involvement in cerebrospinal fluid (CSF) or CNS imaging at time of screening0 - Prior checkpoint inhibitors/ blockade in the last 12 months. - Two prior stem cell transplants of any kind. - One prior autologous stem cell transplant within the preceding 12 months. - Prior allogeneic transplantation. - Prior involved field radiation therapy that would preclude safe delivery of 400cGy total body irradiation (TBI) in the opinion of radiation oncology. - Active and uncontrolled infection at time of transplantation. - HIV infection. - Inadequate performance status/ organ function. - Pregnancy or breast feeding. - Patient or guardian unable to give informed consent or unable to comply with the treatment protocol including appropriate supportive care, long-term follow-up, and research tests.

Exclusion Criteria

Not provided

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall survival

Secondary Outcome Measures

Name	Time	Method
Cumulative incidence of neutrophil and platelet engraftment;Incidences of graft failure;Incidence of grade II-IV and III-IV acute graft-versus-host disease (aGVHD);Incidence of grade II-IV and III-IV aGVHD;Incidence of chronic graft-versus-host disease (cGVHD);Organ distribution of GVHD;Incidence of adverse events;Time to immunosuppression cessation;Pattern of donor chimerism;Incidence of pre-engraftment syndrome (PES);Incidence of transplant related mortality (TRM);Incidence of relapse

Related Trials

A phase II study of Cord blood transplantation for elderly patients with myeloid malignancies using fludarabine and intravenous busulfan in addition to cytarabine and G-CSF.

Not Applicable

JSCT

Updated 10/17/2023

Phase II study of cord blood transplantation using myeloablative conditioning in adult patiants (C-SHOT 0603)

Phase 2

Research Grant on Tissue Engineering from the Japanese Ministry of Health, Labor & Welfare

Updated 10/17/2023

Stem cell transplantation with cord blood and mesenchymal stem cells after reduced intensity conditioning for severe forms of the blistering disease epidermolysis bullosa

Phase 1

niversitair Medisch Centrum Utrecht

Updated 9/10/2018

nrelated cord blood transplantation after reduced toxicity conditioning with mesenchymal stromal cell co-infusion in patients with severe epidermolysis bullosa

CompletedPhase 2

niversitair Medisch Centrum Utrecht

Updated 4/29/2024

Transplantation of umbilical cord blood from unrelated donors in patients with haematological diseases using a myeloablative conditioning regimen - MAC UCBT

niversity College London

Updated 8/4/2015

Reduced-intensity cord blood transplantation (RI-CBT) for refractory hematological malignancies

Phase 2

agoya Blood and Marrow Transplantation Group

Updated 10/17/2023

A feasibility trial of cord blood cell transplantation for adult T cell leukemia/lymphoma following reduced intensity conditioning regime

Not Applicable

Grant for anticancer project from Ministry of Health, Welfare, and Labor of Japan

Updated 10/17/2023

Transplantation of umbilical cord blood (UCB) from unrelated donors (URD) in patients with haematological diseases using a reduced intensity conditioning regimen. - RIC UCBT (Cord Blood)

Phase 1

niversity College London

Updated 7/20/2020